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Background
CXCR4 is a chemokine with numerous effects on the
immune system. In murine lupus models, we observed
an overexpression of CXCR4, and its ligand, CXCL12, in
patients with kidney disease. We assessed whether
CXCR4 and CXCL12 were enhanced in human systemic
lupus erythematosus (SLE) peripheral blood leukocytes
(PBLs) and kidneys.
Methods
PBLs from 24 consecutive SLE patients were prospec-
tively analyzed by flow cytometry for CXCR4 expression.
Human lupus nephritis biopsies (n=16) were immunos-
tained with anti-CXCL12 antibody.
Results
B cells and CD4
+ T cells from SLE patients exhibited an
over two-fold increase (p<0.005) and three-fold increase
(p<0.0005), respectively, in median CXCR4 expression
compared to controls (n=8). Moreover, CXCR4 expres-
sion on B cells was positively associated with disease
activity and increased by 1.61-fold in patients with Sys-
temic Lupus Erythematosus Disease Activity Index
(SLEDAI) scores >10 compared to those with SLEDAI
scores ≤10 (p=0.005), and was 1.36-fold higher in active
neuropsychiatric SLE (NPSLE) patients compared to
non-NPSLE patients (p=0.11). CXCL12 was significantly
up-regulated in lupus nephritis kidneys (n=16), with the
extent and level of expression was correlated with histo-
pathological scores.
Conclusions
CXCR4 is up-regulated in multiple leukocyte subsets in
SLE patients, especially in those with increased disease
severity. The heightened expression of CXCR4 in B cells
in NPSLE, and CXCL12 in nephritic kidneys suggest
that the CXCR4/CXCL12 axis might be a potential tar-
get for therapeutic intervention for patients with renal
SLE and/or NPSLE.
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